Welcome back to Endpoints Weekly! Merck and Moderna dominated the headlines this week with topline results for their personalized cancer vaccine. Check out our team’s detailed analysis on the results ...
August 22, 2026 06:00 AM EDT
Weekly
Third death in China’s expedited trials; Merck and Moderna’s cancer vaccine win; and more
Max Gelman
Nicole DeFeudis
Welcome back to Endpoints Weekly! We’re gearing up for a busy week of earnings coverage, as Moderna, AstraZeneca, GSK, Bristol…
Welcome back to Endpoints Weekly! Don’t miss Ryan Cross’ deep dive into the paranoia caused by competition with China. Ryan…
Welcome back to another edition of Endpoints Weekly! We hope you all have been staying safe indoors as the Canadian wildfires…
Merck and Moderna's mRNA cancer vaccine, an expected nominee to lead the FDA, and more biotech news from The Readout
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and…
Moderna's and Merck's personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring | Fortune
